Is TRT Safe in 2026? What the Latest Research Actually Shows

The Safety Landscape Has Fundamentally Changed

For over a decade, testosterone replacement therapy existed in regulatory limbo. The 2015 FDA black box warning about cardiovascular risks created a generation of physicians who avoided prescribing TRT and patients who feared it was inherently dangerous.

That era officially ended in 2025.

On April 16, 2026, the FDA issued unprecedented guidance signaling a complete regulatory transformation — creating the most permissive pathway for TRT access in modern history. This wasn't political maneuvering; it was the result of definitive clinical evidence that resolved the safety questions that had plagued the field.

What the TRAVERSE Trial Actually Proved

The conversation changed forever when the TRAVERSE trial results were published in the New England Journal of Medicine. This wasn't another small, underpowered study — it was a randomized, placebo-controlled trial of 5,246 men aged 45-80 with hypogonadism, followed for an average of 33 months.

The primary endpoint was clear: major adverse cardiovascular events (heart attack, stroke, death). The results were definitive:

• Testosterone group: 7.0% experienced a major cardiovascular event
• Placebo group: 7.3% experienced a major cardiovascular event

The hazard ratio was 0.96 (95% CI: 0.78-1.17), demonstrating non-inferiority — meaning TRT was statistically equivalent to placebo for cardiovascular safety.

This single study resolved the question that had dominated TRT safety discussions for over a decade: testosterone replacement therapy does not increase the risk of heart attacks or strokes when properly prescribed and monitored.

The FDA's Response: Black Box Warning Removed

Based primarily on TRAVERSE trial data, the FDA took an unprecedented step in early 2025: they removed the cardiovascular black box warnings that had been mandatory on all testosterone products since 2014.

The regulatory impact was immediate. Physicians who had avoided prescribing TRT due to liability concerns suddenly had clear guidance that the cardiovascular risks they'd feared were not supported by the best available evidence.

Then came the April 2026 guidance — creating formal pathways that could "dramatically expand the population of men eligible for FDA-approved TRT." This represented the most significant regulatory shift in men's hormonal health in decades.

Current Safety Profile: What We Know in 2026

Based on the TRAVERSE trial, multiple 2025 meta-analyses, and real-world data from over 9,000 men, here's the current safety profile of TRT:

Cardiovascular: Low Risk

• Heart attack/stroke: No increased risk vs placebo
• Blood pressure: Modest increases requiring monitoring
• Atrial fibrillation: Slightly higher risk (3.5% vs 2.4% in TRAVERSE)

Blood-Related: Manageable

• Elevated hematocrit: Common, managed with periodic therapeutic phlebotomy
• Blood clots: Rare when hematocrit is monitored appropriately

Reproductive: Predictable

• Fertility suppression: Affects 65% of men, typically reversible
• Testicular shrinkage: Common, usually reverses after stopping

Cancer: No Increased Risk

• Prostate cancer: Current evidence shows no increased risk of development or progression

The New Monitoring Standards

While TRT is safer than previously believed, proper monitoring remains essential. The 2026 consensus includes:

Blood Pressure Monitoring

Post-market studies revealed statistically significant blood pressure increases in men on TRT vs placebo. The FDA now requires updated labeling emphasizing blood pressure monitoring, particularly in the first 6 months of treatment.

Laboratory Monitoring

• 6 weeks: Initial response assessment
• 3 months: Comprehensive safety panel
• 6 months: Ongoing monitoring
• Annually: Full hormone panel plus cardiac and prostate markers

Key Markers to Track

• Total and free testosterone
• Hematocrit (target <54%)
• PSA (prostate-specific antigen)
• Blood pressure
• Sleep apnea screening (if applicable)

Fertility: The Predictable Trade-off

Unlike cardiovascular concerns, fertility suppression with TRT is real and predictable. Research shows testosterone acts as a contraceptive, suppressing sperm production in about 65% of normospermic men within 4 months.

The good news: it's typically reversible. About two-thirds of men see sperm return within 6 months of stopping TRT, though 10% might not recover until the second year. For men planning to conceive, fertility preservation through sperm banking is available.

Prostate Cancer: The Persistent Myth

Despite decades of research, no study has documented direct evidence that TRT increases prostate cancer risk. A 2025 scoping review found that "TRT was not associated with increased risk of biochemical recurrence or cancer progression" across 12 studies.

The saturation model explains why: prostate cancer cells need testosterone to grow, but only up to a certain point. Once that threshold is met, additional testosterone doesn't meaningfully affect cancer progression.

Real-World Evidence: 9,537 Men

A major 2025 study provided real-world safety data from 9,537 men treated for testosterone deficiency. The median age was 42, with treatment durations ranging from months to years.

Key findings:

• Consistent efficacy in restoring testosterone levels
• Predictable side effect profile matching clinical trials
• No unexpected safety signals when properly monitored
• High treatment continuation rates suggesting favorable benefit-risk ratio

This real-world data confirmed that clinical trial safety results translate to actual practice when TRT is prescribed by qualified physicians with appropriate monitoring protocols.

Who Shouldn't Consider TRT?

Even with improved safety data, TRT isn't appropriate for everyone:

• Men planning to conceive immediately (without fertility preservation)
• Men with untreated severe sleep apnea
• Men with current prostate cancer (relative contraindication)
• Men with untreated heart failure
• Men with elevated hematocrit (>54%) until managed

The Bottom Line

The 2025-2026 research fundamentally changed the TRT safety conversation. The cardiovascular fears that dominated decision-making for over a decade have been resolved by definitive clinical evidence. The FDA has responded with the most permissive regulatory framework in modern history.

TRT is now considered safe for most men with clinically diagnosed hypogonadism when prescribed by licensed physicians with appropriate monitoring. Blood pressure increases and fertility suppression remain predictable concerns requiring management, but the risk-benefit calculation has shifted decisively toward benefit for symptomatic men with confirmed low testosterone.

For men who have been hesitant about TRT due to safety concerns, 2026 represents a clear inflection point. The evidence base is stronger, the regulatory pathway is clearer, and the monitoring requirements are well-established.

The question is no longer whether TRT is safe — it's whether you have the clinical indication to benefit from it.

Sources

1. Lincoff AM et al. "Cardiovascular Safety of Testosterone-Replacement Therapy." N Engl J Med. 2023;389(2):107-117. https://www.nejm.org/doi/full/10.1056/NEJMoa2215025

1. FDA. "FDA Takes Step Forward on Testosterone Therapy for Men." April 16, 2026. https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

1. Walia et al. "Testosterone Replacement, Where Are We in 2025?" Trends in Urology & Men's Health. 2025. https://onlinelibrary.wiley.com/doi/10.1002/tre.70016

1. Lokeshwar SD et al. "Testosterone replacement therapy following definitive treatment for prostate cancer: a scoping review." Int J Impot Res. 2025. https://www.nature.com/articles/s41443-025-01206-3

1. Real-World Outcomes Study. "Safety of Testosterone Therapy: A Longitudinal, Retrospective Cohort Study of Over 9,000 Men." World J Mens Health. 2025. https://wjmh.org/DOIx.php?id=10.5534%2Fwjmh.250245

1. Centers for Medicare & Medicaid Services. "Long Term Cardiovascular Safety of Testosterone Therapy: A Review of the TRAVERSE Study." PMC. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11937349/